Ask AI
Adjuvant CDK46i Optimization

CE

Myth vs Medicine: Pharmacist’s Perspective on Adjuvant CDK4/6 Inhibitor Optimization

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: March 13, 2026

Expiration: March 12, 2027

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 57-year-old woman with HR+/HER2- early-stage breast cancer has completed adjuvant chemotherapy and radiation. Her pathology shows 2 positive lymph nodes and a 5.2‑cm grade 3 tumor. Her medications include verapamil, and her baseline QTc is 468 ms. She expresses concern about managing adverse effects during treatment while trying to return to work.

Based on the patient’s clinical risk factors, comorbidities, concomitant medications, and treatment goals, which pharmacist-led recommendation best personalizes adjuvant CDK4/6 inhibitor therapy for her?